Commercial Execution Crunch

Even with a positive Phase 3 readout, radioactive peptide drugs require isotopes, specialized manufacturing, trained nuclear-medicine sites, and reimbursement support. The next market focus is whether supply chains can support a commercial launch at scale, especially after Novartis' Pluvicto experience showed the importance of capacity.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.